This study is looking at a medication called orforglipron to see if it's safe and effective for people with Peripheral Artery Disease (PAD). PAD is a condition where narrowed arteries reduce blood flow to your limbs, often causing leg pain when walking (intermittent claudication). You might be able to join if you have symptomatic PAD at Fontaine Stage II and an Ankle Brachial Index (ABI) of 0.9 or less. However, you cannot join if your body mass index (BMI) is too low, your Hemoglobin A1c (HbA1c) is too high, or if other conditions limit your walking. The main goal is to see how much your walking distance improves after 52 weeks. The current status of this study is unclear, and it plans to enroll about 1205 participants.

Study design

This study is interventional, meaning participants will receive either orforglipron or a placebo (an inactive substance). It plans to include about 1205 participants.

What's involved

Participation in this study will last about 58 weeks. The primary measurement of walking distance will be taken at the beginning and at Week 52.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint is measured at Week 52, and the study lasts about 58 weeks, suggesting follow-up for at least 58 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.